Karuna and Incyte scrap programs; More cash for the SPACs
Karuna Therapeutics has built itself into a $2 billion company off the data of an old Eli Lilly drug, when combined with trospium chloride …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
